Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, announced terms for its US offering on Wednesday.
The Paris, France-based company plans to raise $129 million by offering 3.5 million ADSs. Its shares currently trade on the Alternext market of the Euronext Paris under the symbol ALCLS and its last share price was €35, or $36.83. At that price, Cellectis would command a market value of $1.2 billion.
Help employers find you! Check out all the jobs and post your resume.
